Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of preladenant as add-on to levodopa in Parkinson's disease with motor fluctuations
NL-OMON38161Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of preladenant in Parkinson's disease (PD) (5 arms), sponsored by Merck & Co. Primary endpoints: Change in off time and Safety and tolerability. Started Nov 2011; status: active, not recruiting.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON38161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38161.